Arbutus Biopharma Corporation
(NASDAQ:ABUS)

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-del...

Website: http://www.arbutusbio.com

Founded: 2007

Full Time Employees: 78

CEO: William Bill Collier

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2014-03-06	2013-12-31	2013-11-13	2013-08-12	2013-05-14	2012-12-31	2012-11-13	2012-08-14	2012-05-15	2011-12-31	2011-11-08	2011-08-11	2011-05-10	2011-03-30	2010-12-31	2010-11-15

revenue																										1,098,250	3,061,000	653,000	679,000	1,678,000	1,587,000	1,244,000	1,436,000	2,041,500	6,892,000
yoy																										-34.55%	92.88%	-47.51%	-52.72%	-17.81%	-76.97%
qoq																										-64.12%	368.76%	-3.83%	-59.54%	5.73%	27.57%	-13.37%	-29.66%	-70.38%
collaborations and licenses	204,000	792,000	280,000	10,213,000	1,316,000	1,058,000	767,000	1,155,000	939,000	945,000	3,935,000	3,885,000	5,509,000	3,985,000	3,607,000	12,556,000	11,218,000	1,061,000	1,480,000	1,185,000	1,154,000	1,032,000	827,000	825,000
license revenue from genevant	178,741,000
non-cash royalty revenue	181,000	259,000	249,000	526,000	448,000	516,000	572,000	571,000	593,000	1,200,000	723,000	766,000	1,178,000	2,260,000	2,345,000	1,685,000	1,363,000	2,145,000	1,860,000	1,144,000	959,000	1,354,000	696,000	689,000	656,000
total revenue	179,126,000	1,051,000	529,000	10,739,000	1,764,000	1,574,000	1,339,000	1,726,000	1,532,000	2,145,000	4,658,000	4,651,000	6,687,000	6,245,000	5,952,000	14,241,000	12,581,000	3,206,000	3,340,000	2,329,000	2,113,000	2,386,000	1,523,000	1,514,000	1,491,000											1,039,000	235,000	-195,000	774,000	309,000	603,000	12,686,000	4,065,000	3,440,000	4,682,000	4,350,000	4,362,000	1,811,000	4,430,000	15,464,150	7,288,548	3,051,441	2,928,878	2,195,283	3,875,615	3,047,934	3,619,947	3,563,982
operating expenses
research and development	4,120,000	5,006,000	5,778,000	5,498,000	8,959,000	8,810,000	14,273,000	15,551,000	15,403,000	17,564,000	20,169,000	17,692,000	18,275,000	22,949,000	20,055,000	22,942,000	18,462,000	20,437,000	16,299,000	15,396,000	13,370,000	14,535,000	12,065,000	10,465,000	10,416,000	12,418,000	17,731,000
general and administrative	5,889,000	3,689,000	3,044,000	3,328,000	5,832,000	4,712,000	4,537,000	7,547,000	5,312,000	5,101,000	5,842,000	5,980,000	5,552,000	4,249,000	3,493,000	5,200,000	4,892,000	4,698,000	4,146,000	4,445,000	3,847,000	3,540,000	4,065,000	3,566,000	3,553,000	1,877,000	3,249,000	8,189,000	4,412,000	5,927,000	2,631,000	3,775,000	3,669,000	3,543,000	3,659,000	4,599,000	4,328,000	4,733,000	3,720,000	23,766,000	7,219,000	8,354,000	7,706,000	7,662,000	2,716,000	3,082,000	1,764,000	1,787,000	2,050,000	5,546,273	2,764,047	989,061	873,947	919,218	2,405,477	1,504,637	2,403,862	1,821,552	1,968,678	1,207,783	1,594,427	1,541,599	4,780,745	1,222,453	1,482,034
change in fair value of contingent consideration	209,000	-2,657,000	268,000	260,000	299,000	1,890,000	344,000	211,000	180,000	227,000	205,000	-636,000	273,000	1,609,000	215,000	208,000	201,000	193,000	856,000	694,000	129,000	125,000	120,000	116,000	112,000	30,250	376,000
restructuring costs		303,000	98,000	165,000
total operating expenses	10,218,000	6,341,000	9,188,000	9,251,000	27,463,000	15,507,000	22,779,000	23,309,000	20,895,000	22,892,000	26,216,000	23,036,000	24,100,000	28,807,000	23,763,000	28,350,000	23,555,000	24,002,000	21,748,000	20,971,000	17,789,000	18,687,000	16,740,000	14,655,000	14,638,000	14,705,000	94,462,000
income from operations	168,908,000	-5,290,000	-8,659,000		-25,699,000	-13,933,000	-21,440,000	-21,583,000	-19,363,000	-20,747,000	-21,558,000	-18,385,000	-17,413,000	-22,562,000	-17,811,000	-14,109,000	-10,974,000	-20,796,000	-18,408,000	-18,642,000	-15,676,000	-16,301,000	-15,217,000	-13,141,000	-13,147,000	-13,087,000	-91,401,000	-20,515,000	-19,071,000	-16,903,000	-32,426,000	-22,046,000												-14,420,000	-18,006,000	-10,747,000	-6,844,000	-9,423,000	-5,958,000	-12,153,218	-2,145,565	-3,761,446	-3,162,836	-3,083,371	-5,934,273	-1,773,229	-2,582,371	-2,634,936	-2,158,529	-1,682,119	-3,623,039	-3,076,338	-12,515,312	-7,047,344	3,176,111
yoy	-757.26%	-62.03%	-59.61%		32.72%	-32.84%	-0.55%	17.39%	11.20%	-8.04%	21.04%	30.31%	58.68%	8.49%	-3.24%	-24.32%	-29.99%	27.57%	20.97%	41.86%	19.24%	24.56%	-83.35%	-35.94%	-31.06%	-22.58%	181.88%	-6.94%																53.03%	202.22%	-11.57%	218.98%	150.52%	88.38%	294.15%	-63.84%	112.12%	22.48%	17.02%	174.92%	5.42%	-28.72%	-14.35%	-82.75%	-76.13%	-214.07%
qoq	-3292.97%	-38.91%			84.45%	-35.01%	-0.66%	11.47%	-6.67%	-3.76%	17.26%	5.58%	-22.82%	26.67%	26.24%	28.57%	-47.23%	12.97%	-1.26%	18.92%	-3.83%	7.12%	15.80%	-0.05%	0.46%	-85.68%	345.53%	7.57%	12.83%	-47.87%	47.08%													-19.92%	67.54%	57.03%	-27.37%	58.16%	-50.98%	466.43%	-42.96%	18.93%	2.58%	-48.04%	234.66%	-31.33%	-1.99%	22.07%	28.32%	-53.57%	17.77%	-75.42%	77.59%	-321.89%
operating margin %	Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-1191.62%	-2985.98%	-3141.65%	-2808.69%	-1007.33%	-2043.23%	-1772.19%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%
other income
interest income	815,000	877,000	952,000	1,042,000	1,197,000	1,464,000	1,747,000	1,829,000	1,545,000	1,465,000	1,494,000	1,461,000	1,268,000	943,000	694,000	396,000	159,000	30,000	27,000	31,000	39,000	96,000	100,000	200,000	345,000	402,000	503,000	606,000	600,000	728,000	756,000	805,000	758,000	443,000	337,000	390,000	368,000	287,000	425,000	435,000	244,000	208,000	183,000	81,000	202,000	145,000	304,000	257,000	147,000	539,996	108,302	132,891	149,885	148,918	59,061	25,631	29,325	24,214	44,889	17,711	28,995	33,257	106,957	28,130	31,957
interest expense	-17,000	-18,000	-23,000	-28,000	-28,000	-30,000	-29,000	-34,000	-44,000	-44,000	-46,000	-171,000	-198,000	-309,000	-429,000	-482,000	-506,000	-560,000	-762,000	-763,000	-772,000	-797,000	-1,074,000	-1,099,000	-1,041,000	-994,000	-1,100,000	-2,000	-12,000	-122,000
foreign exchange gain	-11,000	1,000	-12,000	21,000	4,000	-33,000	5,000	-8,000	-13,000				4,000			3,000			-15,000	-13,000	28,000	-40,000	-19,000	-47,000		10,750	-25,000	60,000	8,000	-185,000	145,000	-359,000		614,500	1,233,000
total other income	787,000	1,534,000	917,000	1,035,000	1,173,000	1,401,000	1,723,000	1,787,000	1,488,000	1,435,000	1,454,000	1,291,000	1,074,000	630,000	244,000											-11,567,000	-3,758,000	-2,800,000	-4,180,000	-1,346,000	3,671,000	25,137,000	976,000	-2,000	1,297,000	1,230,000		-1,394,000		384,000	4,103,000	5,505,000	13,960,000
net income	169,695,000	-3,756,000	-7,742,000	2,523,000	-24,526,000	-12,532,000	-19,717,000	-19,796,000	-17,875,000	-19,312,000	-20,104,000	-17,094,000	-16,339,000	-21,932,000	-17,567,000	-14,192,000	-15,765,000	-21,321,000	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000	-24,654,000	-82,503,000		-23,251,000			3,091,000	-17,429,000				-18,627,000	-218,695,000	-19,595,000	-130,000,000	-15,874,000			-14,886,000	-11,989,000	-6,168,000	-8,604,000	-6,081,000	-17,984,000	-14,064,226
yoy	-791.90%	-70.03%	-60.73%	-112.74%	37.21%	-35.11%	-1.92%	15.81%	9.40%	-11.95%	14.44%	20.45%	3.64%	2.87%	-8.30%	-26.80%	-3.76%	25.11%	2.15%	37.62%	18.18%	-30.88%	-77.27%		-40.39%				33.40%				-6.43%				17.34%			773.30%	32.40%			144.80%	-33.34%	-56.14%
qoq	-4617.97%	-51.49%	-406.86%	-110.29%	95.71%	-36.44%	-0.40%	10.75%	-7.44%	-3.94%	17.61%	4.62%	-25.50%	24.85%	23.78%	-9.98%	-26.06%	11.29%	-1.18%	18.35%	-3.88%	-9.13%	33.14%	1.63%	-43.78%	-70.12%						-117.73%					-91.48%	1016.08%	-84.93%	718.95%				24.16%	94.37%	-28.31%	41.49%	-66.19%	27.87%
net income margin %	Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-2244.84%	-2695.30%	0%	-3424.30%	0%	0%	248.47%	-1213.72%	0%	0%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
net income per common share
basic	880			10
diluted	870			10
weighted-average number of common shares
basic	193,768,641,000			191,551,282,000																								56,805,583		55,304,083		55,211,294		54,723,272				53,074,401,000				45,462,324,000				21,603,136,000				15,302,680	15,302,680				13,727,925
diluted	195,214,067,000			192,399,733,000																								56,805,583		55,304,083		56,487,220		54,723,272				53,074,401,000				45,462,324,000				21,603,136,000				15,302,680	15,302,680				14,320,814
comprehensive income	169,598,000			2,502,000																																														-17,198,972
unrealized loss on available-for-sale securities	-97,000													516	-907
net loss per common share
basic and diluted		-40	-40																						-250
weighted-average number of common shares
basic and diluted		191,599,600	191,778,950,000		190,707,085	185,608,874	188,997,194	188,041,489	175,625,552	165,960,379	167,512,708	166,063,284	161,643,404	150,939,337	150,995,191	148,750,048	148,428,326	106,242,452	101,286,351	96,869,805	93,434,378	75,835,378	79,487,444	69,604,726	67,683,586,000	57,093,454,000	56,850,172		55,740,121		55,421,504,000		55,071,964		54,877,103,000	54,647,944,000	54,307,464,000		53,652,007,000	52,716,059,000	51,400,485,000		50,756,484,000	54,255,804,000	30,208,136,000		22,159,269,000	22,063,438,000	19,801,428,000			14,511,760	14,406,911	14,344,152		14,006,774	13,999,626	12,779,573	11,318,766	12,139,113	10,617,303	10,341,259	10,332,941	10,332,941	10,335,057
comprehensive loss		29,705,536	-7,684,000		-24,557	-12,577	-19,499	-19,733	-17,825	-18,849	-19,520	-16,928	-15,485	-21,416	-18,474	-14,883	-16,836	-21,469	-19,189	-19,418	-16,378	-17,086	-18,783	-13,965	-13,610,000													-218,695,000	-19,595,000	-130,000,000	-15,874,000			-11,663,000	-21,163,000	-9,446,000	-13,431,000	-2,307,000	-20,143,000
unrealized gain on available-for-sale securities		-5,963	58,000	-21,000	-31	-45	218	63	50	463	584	166	854			-691	-1,071	-148	-31	-31	3	-44	-72	122	251,000
gain from operations				1,488,000
restructuring					12,373,000	906,250	3,625,000
loss per share
basic and diluted					-0.13	-0.07	-0.1	-0.11	-0.1	-0.12	-0.12	-0.1	-0.1	-0.14	-0.12	-0.1	-0.11	-0.15	-0.24	-0.23	-0.21	-0.23	-0.27	-0.25
foreign exchange loss										2,750	6,000	1,000		-4,500	-21,000
income before income taxes										-19,312,000	-20,104,000	-17,094,000	-16,339,000	-21,932,000	-17,567,000	-14,192,000	-11,321,000	-13,731,500	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000	-24,654,000	-95,159,000
income tax expense																	-4,444,000
items applicable to preferred shares:
dividend accretion of convertible preferred shares																		-574,000	-5,087,000	-3,266,000	-3,212,000	-3,123,000	-3,027,000	-2,995,000	-2,978,000
net loss attributable to common shares														-21,932,000	-17,567,000	-14,192,000	-15,765,000	-21,895,000	-24,245,000	-22,653,000	-19,593,000	-20,165,000	-21,782,000	-17,082,000	-16,839,000				-25,966,000				-19,765,000
total other loss																-83,000	-347,000	-525,000	-750,000	-745,000	-705,000	-741,000	-3,538,000	-946,000	-714,000
dividend accretion of convertible preferred shares.
depreciation																		331,500	447,000	436,000	443,000				500,000	507,000	507,000	505,000	509,000
site consolidation																								7,000	57,000	123,000	182,000	-266,000	117,000	1,087,000	-492,000	2,581,000	1,621,000
equity investment loss																							-2,545,000			-2,874,250	-3,512,000	-3,334,000		-709,500	-2,838,000
currency translation adjustments																							44
depreciation and amortization																						372,750	490,000	501,000
impairment of intangible assets																											43,836,000				14,811,000							96,873,000		156,324,000		1,017,000	37,990,000
impairment of goodwill																											22,471,000
arbitration																										-220,000	6,486,000
income tax benefit																											12,656,000			1,070,500	4,282,000							16,216,000		64,864,000		3,799,000	15,196,000
currency translation adjustment
revenue from collaborations and licenses																									835,000
foreign exchange gains																									-18,000											798,000	427,000	-1,060,000		33,000	2,942,000	5,503,000	11,801,000	-2,571,000	7,038,000	2,336,000	3,076,000		1,443,000	1,079,310	1,093,735	54,016	-62,982	-5,459	-36,931	56,891	-5,331	10,210				-54,628	-7,125	-912	25,435
net equity investment loss
gain on investment																																24,884,000
accrual of coupon on convertible preferred shares																										-2,067,250	-2,792,000	-2,762,000	-2,715,000	-2,647,000	-2,567,000	-2,541,000
net loss attributable to common shareholders																										-34,334,500	-85,295,000
net loss attributable to common shareholders, per share
basic and diluted																										-0.608	-1.5		-0.47				-0.36
expenses
research, development, collaborations and contracts																												12,740,000	14,712,000	11,717,750	16,566,000	16,356,000	13,949,000	17,822,000	15,537,000	15,445,000	13,872,000	17,156,000	15,738,000	15,215,000	13,144,000	14,904,000	16,354,000	9,690,000	10,557,000			9,298,000	8,204,000	21,458,258	6,537,630	5,670,974	5,060,845	4,188,809	7,220,857	3,101,825	3,572,507	4,136,529	3,680,298	4,380,947	6,198,149	5,639,575	22,133,983	6,625,644	5,222,622
total expenses																												21,168,000	19,750,000	18,581,000	34,013,000	23,290,000	19,841,000	62,783,000	19,789,000	20,524,000	18,534,000	257,244,000	19,749,000	195,557,000	20,580,000	24,444,000	62,203,000	17,860,000	22,688,000	15,097,000	11,206,000	11,234,000	10,388,000	27,617,368	9,434,113	6,812,887	6,091,714	5,278,654	9,809,888	4,821,163	6,202,318	6,198,918
decrease in fair value of contingent consideration																												-130,000	-125,000	1,035,000	5,608,000	-193,000	848,000			110,000
net income before income taxes																												-23,315,000
net income attributable to common shares																												-26,077,000				550,000
net income attributable to common shareholders, per share
basic																												-0.46				0.01
diluted																												-0.46				0.01
equity investment																													-4,651,000
depreciation of property and equipment																														504,000	497,000	578,000	602,000	620,000	593,000	480,000	334,000	332,000	291,000	252,000	217,000	169,000	153,000	147,000	120,000	113,000	133,000	149,000	134,000	612,837	132,436	152,852	156,922	170,627	183,554	214,701	225,949	240,837	244,779	253,798	238,286	238,649	1,038,573	482,254	202,039
increase in fair value of warrant liability																																													-1,223,000	2,560,000	-5,140,000				-554,937	-2,508,059			-405,519.5	-1,744,734
net (loss) before income taxes																														-10,773,250	-28,755,000
net																														-9,702,750	-24,473,000
net (loss) attributable to common shares																														-11,563,750	-27,040,000
basic and diluted																														-210	-490
decrease in fair value of warrant liability																																						191,000	10,000	168,000	161,000	564,000	1,976,000	2,024,000				5,813,000	-13,616,000	-3,530,314			-29,186	317,497
items applicable to preferred shares
gain on disposition of financial instrument																																									1,000,000
increase in fair value of contingent consideration
net and comprehensive loss																																		-12,120,500	-11,600,000	-18,255,000
loss per common share
basic and diluted																																		-222.5	-210	-330	-340	-787.5	-370	-2,470	-310			-270	-400	-382.5	-390	-280			-0.205	-0.42	-0.22	-0.18	-0.158	-0.25	-0.14	-0.25	-0.15	-0.12	-0.33	-0.3	-1.2	-0.11	-0.26
collaborations and contracts																																				318,000	18,000	3,000	87,000	32,000	107,000	4,444,000	3,035,000	2,310,000	3,520,000	3,327,000	3,578,000	1,144,000	3,689,000	10,424,569	2,251,067	3,049,341	2,928,878	2,195,283	3,875,615	2,055,934	2,601,847	3,563,982	3,735,226	3,636,309	4,407,823	4,343,485	14,923,860	6,192,406	3,949,356
licensing fees, milestone and royalty payments																																				721,000	217,000	-198,000	687,000	277,000	496,000	8,242,000	1,030,000	1,130,000	1,162,000			667,000	741,000	5,039,581	5,037,481	2,100
acquisition costs																																												361,000	9,295,000
cumulative translation adjustment																																												3,223,000	-9,174,000	-3,278,000	-4,827,000	3,774,000	-2,159,000	-3,134,746
licensing fees, milestone and
royalty payments																																														548,000	784,000
research, development, collaborations
and contracts																																														6,702,750	9,309,000
foreign exchange losses																																																-2,728,000											132,594	-82,322	-10,166
income per common share
basic and diluted																																																	-910
licensing settlement payment
licensing settlement legal fees
warrant issuance costs																																																										-47,000			-80,000
income per common share
basic																																																		-0.92
diluted																																																		-0.92
net loss and comprehensive loss																																																			-2,952,533	-6,082,598	-3,105,119	-2,622,415	-2,129,668.5	-3,435,441	-1,923,355	-3,159,878	-1,837,854	-1,469,295	-3,532,068	-3,097,709	-12,415,480	-1,103,376	-2,683,247
licensing fees and milestone payments																																																								992,000	1,018,100			524,100			514,129		514,129
change in fair value of warrant liability																																																									635,022	-512,366	143,192	277,435	152,142
license amendment payment																																																															5,916,750		5,916,750
loss on purchase and settlement of exchangeable and development notes																																																															5,916,750	11,833,500	-5,916,750
expenses - sum																																																											5,323,303.25	5,842,528	8,030,862	7,419,823	33,870,051	13,239,750	7,204,124
termination and restructuring expenses
in-process research and development acquired from protiva
impairment loss on goodwill
amortization of intangible assets																																																																251,837.75	297,429

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2014-03-06	2013-12-31	2013-11-13	2013-08-12	2013-05-14	2012-12-31	2012-11-13	2012-08-14	2012-05-15	2011-12-31	2011-11-08	2011-08-11	2011-05-10	2011-03-30	2010-12-31	2010-11-15

assets
current assets:
cash and cash equivalents	23,706,000	18,008,000	22,408,000	37,412,000	37,076,000	36,330,000	31,846,000	62,788,000	43,101,000	26,285,000	17,531,000	27,197,000	40,574,000	30,776,000	24,004,000	47,320,000	81,330,000	109,282,000	77,883,000	30,954,000	79,421,000	52,251,000	96,918,000	45,899,000	26,416,000	31,799,000	90,082,000	78,872,000	83,969,000	36,942,000	21,933,000	10,193,000	12,461,000	54,292,000	15,225,000	24,212,000	29,851,000	23,413,000	26,630,000	42,970,000	144,772,000	166,779,000	181,089,000	207,205,000	232,276,000	72,187,000	78,177,000	85,267,000	134,357,000	68,716,531	68,716,531	36,919,072	40,736,004	43,809,923	46,785,518	5,632,892	6,937,728	8,745,074	9,184,134	9,215,249	9,711,620	9,228,665	12,346,010	12,346,010	15,899,130
investments in marketable securities, current	71,520,000	73,463,000	71,294,000	60,676,000	75,631,000	86,293,000	95,948,000	79,198,000	86,139,000	99,718,000	116,649,000	125,287,000	106,154,000	116,137,000	110,714,000	102,879,000	84,147,000	46,035,000	43,520,000	47,425,000	52,540,000	71,017,000	21,378,000	36,489,000	58,475,000
accounts receivable	1,312,000	1,447,000	905,000	1,025,000	1,182,000	2,409,000	1,608,000	1,767,000	2,139,000	1,776,000	2,171,000	2,614,000	2,664,000	1,352,000	1,835,000	1,970,000	1,313,000	899,000	1,667,000	1,298,000	1,265,000	1,312,000	1,075,000	1,108,000	1,072,000	1,204,000	2,488,000	1,531,000	923,000	1,431,000	538,000	1,322,000	719,000	402,000	846,000	1,042,000	7,878,000	273,000	395,000	456,000	340,000	1,008,000	2,192,000	6,332,000	4,564,000	1,903,000	2,094,000	299,000	1,521,000	116,556	116,556	4,106,997	1,732,156	1,493,170	1,069,437	1,949,664	1,849,666	2,385,201	880,693	1,542,545	4,152,130	3,320,363	3,318,729	3,318,729	2,120,248
license receivable from genevant	178,741,000
prepaid expenses and other current assets	1,732,000	1,538,000	2,835,000	4,006,000	2,919,000	2,284,000	3,375,000	4,467,000	4,493,000	4,248,000	5,256,000	3,702,000	3,462,000	2,874,000	4,583,000	5,622,000	5,908,000	4,445,000	3,466,000	3,789,000	4,115,000	3,124,000	1,871,000	2,040,000	2,370,000		1,771,000	2,770,000
total current assets	277,011,000	94,456,000	97,442,000	103,119,000	116,808,000	127,316,000	132,777,000	148,220,000	135,872,000	132,027,000	141,607,000	158,800,000	152,854,000	151,139,000	141,136,000	157,791,000	172,698,000	160,661,000	126,536,000	83,466,000	137,341,000	127,704,000	121,242,000	85,536,000	88,333,000	93,828,000	94,341,000	99,583,000	112,486,000	129,229,000	144,025,000	157,769,000	175,186,000	129,366,000	90,813,000	105,922,000	120,268,000	132,564,000	151,812,000	168,085,000	174,757,000	183,882,000	200,027,000	215,702,000	239,769,000	116,418,000	111,737,000	118,164,000	137,001,000	70,342,653	70,342,653	43,338,000	46,862,235	49,995,931	50,983,446	8,603,775	10,087,447	12,703,488	11,793,713	12,983,675	15,760,650	13,989,140	17,908,827	17,908,827
property and equipment	22,000	32,000	137,000	148,000	168,000	3,309,000	3,556,000	4,059,000	4,414,000	4,674,000	5,033,000	5,370,000	4,853,000	5,070,000	5,241,000	5,493,000	5,664,000	5,983,000	6,352,000	6,779,000	6,584,000	6,927,000	7,262,000	7,741,000	8,176,000	8,676,000		9,402,000	9,667,000		16,813,000	16,576,000	25,080,000	24,854,000	24,747,000	24,284,000	22,523,000	17,683,000	14,555,000	14,121,000	13,167,000	12,912,000	12,243,000	12,469,000	11,925,000	12,959,000	13,093,000	13,589,000	13,367,000	13,038,751	13,038,751	13,668,214	13,545,049	13,327,808	13,121,268	18,693,441	18,697,257	18,685,330	18,684,491	18,725,345	18,725,345	18,724,155	3,113,416	3,113,416	3,028,849
other non-current assets	131,000	130,000	131,000		34,000	34,000					3,000	11,000	62,000	103,000	167,000	180,000	190,000	61,000				44,000	109,000	173,000	233,000	293,000
total assets	277,164,000	94,618,000	97,710,000	103,267,000	117,010,000	131,707,000	140,441,000	160,043,000	150,290,000	144,401,000	158,641,000	176,823,000	191,224,000	195,419,000	203,801,000	215,836,000	236,877,000	204,485,000	165,596,000	135,376,000	146,240,000	137,080,000	131,104,000	97,625,000	102,614,000	105,535,000	117,277,000	192,570,000	209,216,000	227,905,000	245,418,000	277,014,000	270,026,000	237,161,000	239,845,000	255,075,000	268,140,000	275,919,000	514,730,000	530,861,000	703,254,000	712,291,000	722,631,000	773,820,000	787,064,000	118,178,000	125,059,000	132,068,000	138,522,000	71,715,810	71,715,810	44,749,417	48,303,339	51,376,715	52,328,318	10,130,146	11,831,007	14,661,069	13,991,292	15,422,806	18,453,579	16,919,165	21,022,243	21,022,243
liabilities and stockholders’ equity
current liabilities:
accounts payable and accrued liabilities	4,474,000	5,459,000	4,653,000	4,508,000	12,109,000	7,564,000	7,544,000	11,108,000	8,247,000	10,271,000	9,806,000	8,805,000	9,653,000	16,029,000	12,268,000	12,474,000	8,715,000	10,838,000	9,727,000	8,352,000	6,063,000	8,901,000	6,913,000	5,813,000	3,565,000	7,098,000	8,199,000	7,940,000	6,828,000	9,429,000	8,511,000	7,385,000	6,459,000	10,646,000	6,403,000	8,274,000	7,428,000	9,910,000	7,132,000	7,753,000	7,711,000	8,827,000	7,501,000	6,920,000	14,019,000	9,328,000	5,904,000	3,780,000	4,594,000	3,680,462	3,680,462	4,412,527	5,188,098	4,596,062	3,776,287	3,033,362	2,956,847	3,065,337	3,972,551	3,730,888	4,642,506	4,692,242	6,151,923	6,151,923	4,400,328
lease liability, current	631,000	547,000	531,000	514,000	563,000	483,000	468,000	453,000	502,000	425,000	412,000	397,000	446,000	372,000	360,000	377,000	439,000	383,000	386,000	357,000	432,000	390,000	378,000	364,000	408,000	340,000	329,000	376,000	599,000
total current liabilities	5,105,000	6,006,000	5,184,000	5,022,000	19,431,000	15,618,000	18,923,000	22,595,000	20,296,000	22,487,000	22,324,000	24,529,000	25,154,000	32,857,000	27,506,000	29,824,000	32,409,000	11,221,000	10,113,000	8,841,000	6,693,000	9,541,000	7,608,000	6,327,000	4,031,000	7,828,000	8,817,000	8,799,000	8,823,000	11,239,000	12,668,000	11,541,000	10,396,000	14,627,000	8,235,000	11,881,000	10,871,000	10,585,000	8,392,000	10,084,000	11,112,000	10,578,000	13,831,000	16,131,000	24,875,000	20,206,000	19,488,000	16,413,000	23,039,000	12,522,489	12,522,489	13,971,188	12,512,257	12,533,495	10,898,365	8,793,183	6,939,935	7,761,826	6,985,493	6,647,301	8,207,906	7,080,638	8,134,187	8,134,187
liability related to sale of future royalties	3,278,000	3,442,000	3,684,000	3,910,000	4,409,000	4,829,000	5,315,000	5,859,000	6,396,000	6,953,000	8,110,000	8,787,000	9,384,000	10,365,000	12,316,000	14,233,000	15,439,000	16,296,000	17,883,000	18,982,000	19,366,000	19,554,000	20,117,000	19,739,000	19,375,000	18,992,000	18,675,000
contingent consideration	8,604,000	8,395,000	11,052,000	10,784,000	10,524,000	10,225,000	8,335,000	7,991,000	7,780,000	7,600,000	7,373,000	7,168,000	7,804,000	7,531,000	5,922,000	5,707,000	5,499,000	5,298,000	5,105,000	4,249,000	3,555,000	3,426,000	3,301,000	3,181,000	3,065,000	2,953,000	3,005,000	3,381,000	3,251,000	3,126,000	4,161,000	9,769,000	9,576,000	10,424,000	10,211,000	10,014,000	10,124,000	9,065,000	8,253,000	7,993,000	7,741,000	7,497,000	6,665,000	5,136,000	4,736,000
lease liability, non-current		199,000	391,000	575,000	626,000	806,000	978,000	1,144,000	1,181,000	1,343,000	1,497,000	1,646,000	1,671,000	1,815,000	1,955,000	2,088,000	2,100,000	2,231,000	2,355,000	2,475,000	2,477,000	2,593,000	2,733,000	2,867,000	2,887,000	3,018,000	3,143,000	3,263,000	3,272,000
total liabilities	16,987,000	18,042,000	20,311,000	20,291,000	37,853,000	34,341,000	33,551,000	37,589,000	35,653,000	38,383,000	39,304,000	42,130,000	47,309,000	58,567,000	58,284,000	62,694,000	71,032,000	35,046,000	35,456,000	34,547,000	32,091,000	35,114,000	33,759,000	32,114,000	29,358,000	32,791,000	33,640,000	28,104,000	28,007,000	27,671,000	30,146,000	38,942,000	37,608,000	54,688,000	72,454,000	79,289,000	79,042,000	72,914,000	98,105,000	99,537,000	165,177,000	164,612,000	168,824,000	185,319,000	193,373,000	30,143,000	29,563,000	26,923,000	33,039,000	12,522,489	12,522,489	13,971,188	12,512,257	12,848,507	11,617,144	9,821,023	8,230,739	9,287,672	8,676,022	8,521,102	10,293,999	9,194,485	10,289,665	10,289,665
stockholders’ equity
common shares																																																										236,553,069
authorized: unlimited number without par value
issued and outstanding: 196,947,757	1,444,494,000
additional paid-in capital	74,256,000	83,318,000	83,285,000	82,628,000	82,089,000	82,048,000	81,425,000	81,751,000	80,220,000	81,270,000	79,546,000	77,202,000	74,238,000	72,406,000	70,738,000	69,134,000	67,151,000	65,485,000	64,096,000	63,933,000	62,133,000	60,751,000	59,614,000	58,300,000	56,803,000	55,246,000	55,385,000	53,738,000	49,594,000	48,084,000	45,500,000	44,429,000	43,769,000	42,840,000	40,755,000	39,758,000	37,809,000	36,543,000	34,486,000	32,817,000	30,243,000	30,206,000	28,538,000	27,844,000	28,590,000	26,208,000	25,872,000	25,655,000	24,837,000	25,343,481	25,343,481	31,893,102	31,686,749	31,577,891	31,520,480	31,068,891	30,977,552	30,827,893	30,661,704	30,411,331	30,301,410	30,217,280	30,151,810	30,151,810
deficit	-1,210,378,000	-1,380,073,000	-1,376,317,000	-1,368,575,000	-1,371,098,000	-1,346,572,000	-1,334,040,000	-1,314,323,000	-1,294,527,000	-1,276,652,000	-1,257,340,000	-1,237,236,000	-1,220,142,000	-1,203,803,000	-1,181,871,000	-1,164,304,000	-1,150,112,000	-1,134,347,000	-1,112,452,000	-1,088,207,000	-1,065,554,000	-1,045,961,000	-1,025,796,000	-1,004,014,000	-986,932,000	-970,093,000	-942,559,000	-857,264,000	-831,187,000	-805,221,000	-784,325,000	-757,285,000	-757,835,000	-738,070,000	-699,631,000	-688,031,000	-669,776,000	-651,149,000	-432,454,000	-412,859,000	-282,859,000	-266,985,000		-232,739,000	-217,853,000	-205,864,000	-199,696,000	-191,092,000	-185,011,000	-167,026,633	-167,026,633	-240,864,771	-234,782,173	-231,677,054	-229,054,639	-267,366,361	-263,930,920	-262,007,565	-258,847,687	-257,009,833	-255,540,538	-252,008,470	-248,910,761	-248,910,761	-233,163,656
accumulated other comprehensive loss	-48,195,000	-48,098,000	-48,129,000	-48,187,000	-48,166,000	-48,135,000	-48,090,000	-48,308,000	-48,371,000	-48,421,000	-48,884,000	-49,468,000	-49,634,000	-50,488,000	-51,004,000	-50,097,000	-49,406,000	-48,335,000	-48,187,000	-48,199,000	-48,168,000	-48,171,000	-48,127,000	-48,099,000	-47,977,000	-48,229,000	-48,217,000	-48,244,000	-48,192,000	-48,170,000	-48,197,000	-48,185,000	-48,185,000	-48,185,000	-49,782,000	-49,782,000	-49,782,000	-49,782,000	-49,782,000	-49,782,000	-49,782,000	-49,782,000		-28,264,000	-31,487,000	-22,313,000	-19,035,000
total stockholders’ equity	260,177,000		77,399,000	82,976,000	79,157,000		106,890,000	122,454,000	114,637,000		119,337,000	134,693,000	143,915,000		145,517,000	153,142,000	165,845,000		130,140,000	100,829,000	114,149,000		97,345,000	65,511,000	73,256,000																											30,778,229	35,791,082	38,528,208	40,711,174	309,123	3,600,268	5,373,397	5,315,270	6,901,704	8,159,580	7,724,680	10,732,578	10,732,578
total liabilities and stockholders’ equity	277,164,000		97,710,000	103,267,000	117,010,000		140,441,000	160,043,000	150,290,000		158,641,000	176,823,000	191,224,000		203,801,000	215,836,000	236,877,000		165,596,000	135,376,000	146,240,000		131,104,000	97,625,000	102,614,000																											44,749,417	48,303,339	51,376,715	52,328,318	10,130,146	11,831,007	14,661,069	13,991,292	15,422,806	18,453,579	16,919,165	21,022,243	21,022,243
right of use asset						1,048,000	1,144,000	1,237,000	1,327,000	1,416,000	1,502,000	1,585,000	1,665,000	1,744,000	1,821,000	1,922,000	2,007,000	2,092,000	2,174,000	2,225,000	2,315,000	2,405,000	2,491,000	2,575,000	2,657,000	2,738,000	2,817,000	2,901,000	3,081,000
liabilities and stockholders' equity
deferred license revenue, current					6,759,000	7,571,000	10,911,000	11,034,000	11,547,000	11,791,000	12,106,000	15,327,000	15,055,000	16,456,000	14,878,000	16,973,000	23,255,000
deferred license revenue, non-current					2,863,000	2,863,000							3,296,000	5,999,000	10,585,000	10,842,000	15,585,000
issued and outstanding: 192,531,225 and 189,963,492 as of december 31, 2025 and 2024, respectively.		1,421,429,000
total stockholders' equity		76,576,000				97,366,000				106,018,000				136,852,000				169,439,000				101,966,000				72,744,000	83,637,000	164,466,000	181,209,000	200,234,000	215,272,000	238,072,000	232,418,000	182,473,000	167,391,000	175,786,000	189,098,000	203,005,000	416,625,000	431,324,000	538,077,000	547,679,000	553,807,000	588,501,000	593,691,000	88,035,000	95,496,000	105,145,000	105,483,000	59,193,321	59,193,321
total liabilities and stockholders' equity		94,618,000				131,707,000				144,401,000				195,419,000				204,485,000				137,080,000				105,535,000	117,277,000	192,570,000	209,216,000	227,905,000	245,418,000	277,014,000	270,026,000	237,161,000	239,845,000	255,075,000	268,140,000	275,919,000	514,730,000	530,861,000	703,254,000	712,291,000	722,631,000	773,820,000	787,064,000	118,178,000	125,059,000	132,068,000	138,522,000	71,715,810	71,715,810
issued and outstanding: 191,953,665			1,418,560,000
issued and outstanding: 191,641,511				1,417,110,000
issued and outstanding: 191,481,474					1,416,332,000
investments in marketable securities, non-current							2,964,000	6,527,000	8,677,000	6,284,000	10,496,000	11,057,000	31,790,000	37,363,000	55,436,000	50,450,000	56,318,000	35,688,000	30,534,000	42,906,000				1,600,000	3,215,000
issued and outstanding: 189,963,492 and 169,867,414 as of december 31, 2024 and 2023, respectively.						1,410,025,000
issued and outstanding: 189,438,135							1,407,595,000
issued and outstanding: 188,739,044								1,403,334,000
issued and outstanding: 180,192,227									1,377,315,000
issued and outstanding: 169,867,414 and 157,455,363 as of december 31, 2023 and 2022, respectively.										1,349,821,000
issued and outstanding: 167,695,247											1,346,015,000
issued and outstanding: 166,922,739												1,344,195,000
issued and outstanding: 165,132,193													1,339,453,000
issued and outstanding: 157,455,363														1,318,737,000
issued and outstanding: 152,711,702															1,307,654,000
issued and outstanding: 148,794,262																1,298,409,000
issued and outstanding: 148,728,237																	1,298,212,000
stockholders' equity
preferred shares
issued and outstanding: 0
issued and outstanding: 144,987,736																		1,286,636,000
issued and outstanding: 1,164,000																			160,973,000	155,886,000	152,620,000	149,408,000	146,285,000	143,258,000	140,263,000	137,285,000	134,405,000	131,613,000	128,851,000	126,136,000	123,489,000	120,922,000	118,381,000
issued and outstanding: 110,264,915																			1,065,710,000
liability-classified options																				132,000	198,000	250,000	317,000	150,000	58,000	253,000	86,000	141,000	414,000	479,000	2,738,000	2,092,000	1,188,000	1,239,000	1,817,000	983,000	819,000	553,000	948,000	1,312,000	1,755,000
issued and outstanding: 97,700,016																				1,017,416,000
issued and outstanding: 96,245,371																					1,013,118,000
issued and outstanding: 89,678,722																						985,939,000
issued and outstanding: 84,618,575																							965,369,000
issued and outstanding: 71,256,579 (december 31, 2019: 64,780,314																								916,066,000
stockholders’ equity:
issued and outstanding: 68,961,395																									911,099,000
investments in marketable securities																										59,035,000
prepaid expenses and other assets																										1,790,000			682,000	2,792,000	1,127,000	1,236,000	1,457,000	2,144,000	1,500,000	1,583,000	1,575,000	1,311,000	1,459,000	2,043,000	1,469,000	1,196,000	1,234,000	1,787,000	1,255,000	1,730,000	696,000	335,000	561,000	1,084,030	1,084,030	892,522	854,828	829,512	327,609	425,507	344,549	516,156	424,387	665,180	421,525	270,621	315,057	315,057	235,786
investment in genevant																											10,969,000	14,377,000	17,675,000	22,224,000	24,665,000	27,446,000
intangible assets																												43,836,000	43,836,000	43,836,000	43,836,000	58,647,000	58,647,000	58,647,000	99,445,000	99,445,000	99,445,000	99,445,000	196,318,000	196,318,000	352,642,000	352,642,000	353,601,000	390,017,000	389,652,000																				14,194,755
goodwill																												22,471,000	22,471,000	22,471,000	22,471,000	22,471,000	24,364,000	24,364,000	24,364,000	24,364,000	24,364,000	24,364,000	162,514,000	162,514,000	162,514,000	162,514,000	156,637,000	156,053,000	155,865,000
site consolidation accrual																										137,000	203,000	342,000	982,000	1,331,000	770,000	1,090,000	1,029,000
deferred rent and inducements, non-current
deferred tax liability																												12,661,000	12,661,000	12,661,000	12,661,000	16,943,000	16,943,000	16,943,000	41,263,000	41,263,000	41,263,000	41,263,000	81,460,000	81,460,000	146,324,000	146,324,000	141,440,000	156,007,000	155,865,000
authorized: unlimited number with no par value
issued and outstanding: 64,780,314																										898,535,000
short-term investments																												16,410,000	26,621,000	87,675,000	120,085,000	144,676,000	160,079,000	72,060,000	72,954,000	78,797,000	80,528,000	107,146,000	123,052,000	122,340,000	27,802,000	14,525,000	15,006,000			39,974,000	30,580,000	31,966,000
property and equipment, net accumulated depreciation 8,612																											9,150,000
authorized: 1,164,000 without par value
issued and outstanding: 56,850,172																											884,623,000	884,623,000
authorized - 1,164,000 without par value
authorized - unlimited number without par value
investment tax credits receivable																													291,000	389,000	342,000	342,000	342,000	340,000	160,000	160,000	308,000	293,000	148,000	148,000	246,000	246,000	52,000	55,000	79,000	86,000	38,000	40,000	39,000	40,200	40,200		9,825	9,825	9,825	9,825	217,460	331,032	331,032	321,208	321,208	403,580	403,580	403,580	254,533
authorized - 1,164,000 with no par value
authorized - unlimited number with no par value
issued and outstanding: 56,255,816																													882,143,000
accrued revenue																																	128,000	128,000	128,000	128,000	128,000	128,000	128,000	128,000	128,000	128,000	454,000	323,000	1,595,000	538,000	152,000	200,000	412,000	212,384	212,384	1,164,840	3,222,836	3,485,598	2,361,836	97,776	108,587	53,477	185,356	750,290	379,438	202,754	817,464	817,464	414,892
restricted investment																																		12,601,000	12,601,000	12,601,000	12,601,000	12,601,000
property and equipment,																														10,145,000
deferred revenue																															649,000	974,000	1,720,000	2,742,000	15,000	2,624,000	2,624,000	15,000	15,000	711,000	924,000	868,000	4,835,000	5,605,000	5,233,000	5,779,000	4,877,000	6,043,000	5,621,000	3,463,255	3,463,255	4,453,488	3,962,136	4,423,556	3,127,629	3,082,341	3,050,342	3,128,721	2,807,898						5,585,234
deferred rent and inducements, long term																														645,000				693,000
loan payable																																		12,001,000	12,001,000	12,001,000	12,001,000	12,001,000
issued and outstanding: 55,518,800																														879,405,000
less accumulated depreciation																															-6,392,000	-5,895,000	-13,251,000	-12,671,000	-12,125,000	-11,541,000	-11,061,000	-10,738,000	-10,469,000	-10,177,000	-9,925,000	-9,729,000		-10,433,000	-10,147,000	-11,199,000	-11,480,000	-11,913,000	-11,846,000	-11,665,594	-11,665,594	-12,256,797	-12,103,945	-11,947,024
deferred lease incentives, net of current portion																															656,000	689,000	693,000		744,000
issued and outstanding: 55,472,319																															878,805,000
restricted cash
issued and outstanding: 55,325,250																																878,191,000
issued and outstanding: 55,087,191																																	876,288,000
long-term investments																																									10,099,000	10,070,000	10,041,000	10,012,000			11,709,000	12,228,000
warrants																																						107,000	297,000	308,000	722,000	883,000	1,495,000	3,606,000	5,623,000	5,099,000	8,707,000	6,590,000	12,824,000	5,378,772	5,378,772	5,105,173	3,362,023	3,513,877	3,994,449	2,677,480	932,746	1,567,768	205,044	313,232	590,667
deferred revenue, net of current portion																																				4,130,000	4,783,000					213,000	6,888,000	8,045,000	7,897,000	9,937,000	10,075,000	10,510,000	10,000,000					315,012	718,779	1,027,840	1,290,804	1,525,846	1,690,529	1,873,801	2,086,093	2,113,847	2,155,478	2,155,478
issued and outstanding: 500,000																																		49,780,000
issued and outstanding: 55,060,662																																		876,108,000
issued and outstanding: 55,051,983																																			876,049,000
issued and outstanding: 55,026,983																																				873,841,000
issued and outstanding: 55,024,545																																					870,847,000
issued and outstanding: 54,841,494																																						867,393,000	864,375,000
issued and outstanding: 54,796,741																																								861,148,000
issued and outstanding: 54,625,691																																									840,475,000
issued and outstanding: 54,570,691																																										834,240,000
depreciation																																											2,325,000				1,613,000
issued and outstanding: 54,569,791																																											828,578,000
issued and outstanding: 54,303,402																																												821,660,000
issued and outstanding: 54,095,921																																													814,441,000
deferred expenses																																																57,000	111,000	172,952	172,952	254,569	306,586	367,903	429,221	488,111	629,457	672,548	788,111	489,203	563,682	563,157	557,256	557,256	187,101
issued and outstanding: 22,438,169																																														290,004,000
issued and outstanding: 22,281,877																																															288,355,000
issued and outstanding: 22,079,727																																																284,790,000
accumulated other comprehensive income																																																-14,208,000	-17,983,000	-15,825,386	-15,825,386
common shares (note 5) authorized - unlimited number with no par value
issued and outstanding: 21,992,088																																																	283,640,000
issued and outstanding: 19,048,900																																																		216,701,859	216,701,859
authorized—unlimited number with no par value
issued and outstanding:
14,554,211																																																				239,749,898
property and equipment net of accumulated depreciation																																																					1,441,104	1,380,784
14,423,401																																																					238,886,506
14,376,714																																																						238,627,371
nature of business and future operations
contingencies and commitments
less accumulated depreciation and impairment																																																							-11,776,396	-17,167,070	-16,953,697	-16,727,749	-16,486,912	-16,286,214	-16,032,416	-15,794,130
property and equipment net of accumulated depreciation and impairment																																																							1,344,872	1,526,371	1,743,560	1,957,581	2,197,579
authorized - unlimited number with no par value issued and outstanding:
14,305,356																																																							238,245,333
authorized — unlimited number with no par value
14,007,854																																																								236,606,593
nature of business, future operations and summary of significant accounting policies
subsequent event
13,999,661																																																									236,553,636
basis of presentation and future operations
finished goods inventory																																																													211,047		150,731	150,731
12,148,636																																																											233,501,253
deferred revenue current portion																																																												2,603,181	2,974,733	2,388,396	1,982,264	1,982,264
12,148,474																																																												233,500,206
12,131,834																																																													233,398,708
authorized - unlimited number with no par value issued and outstanding: 10,341,934																																																														229,515,870
contingencies
liabilities and shareholders’ equity
commitments and contingencies
issued and outstanding - 10,338,703																																																															229,491,529	229,491,529
current assets: - sum																																																																	19,111,690
current liabilities: - sum																																																																	9,985,562
shareholders’ equity:
issued and outstanding - 10,337,414																																																																	229,487,110
contributed surplus																																																																	30,026,278
authorized - unlimited number with no par value - sum																																																																	26,349,732

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-11-13	2013-08-12	2013-05-14	2012-12-31	2012-11-13	2012-08-14	2012-05-15	2011-12-31	2011-11-08	2011-08-11	2011-05-10

operating activities
net income	169,695,000				-24,526,000
non-cash items:
depreciation	11,000		11,000	11,000	330,000	333,000	336,000	356,000	355,000	359,000	369,000	342,000	334,000	307,000	343,000	383,000	394,000	427,000	447,000	436,000	443,000	487,000	490,000	501,000	500,000	1,521,000
loss on impairment of leasehold improvements and lab equipment		0	0	0	2,811,000
stock-based compensation expense	1,359,000	1,262,000	1,263,000	864,000	3,564,000	1,632,000	2,160,000	3,180,000	2,014,000	1,723,000	2,483,000	2,964,000	2,131,000	1,667,000	1,715,000	2,064,000	1,736,000	1,431,000	1,615,000	1,743,000	1,635,000	1,431,000	1,688,000	1,597,000	1,445,000	5,283,000	-2,268,000	2,262,000	1,522,000																					676,532	110,437	-18,463	134,499	841,000	-9,270	-28,722	178,648	423,853	118,136	-4,245	88,375
change in fair value of contingent consideration	209,000	-2,657,000	268,000	260,000	299,000	1,890,000	344,000	211,000	180,000	227,000	205,000	-636,000	273,000	1,609,000	215,000	208,000	201,000	193,000	856,000	694,000	129,000	125,000	120,000	116,000	112,000	203,000	-506,000	5,000	125,000	-1,690,000	-5,801,000	1,041,000	-848,000	1,162,000	307,000	-1,169,000	1,059,000	1,308,000	8,000	8,000	244,000
non-cash royalty revenue	-181,000	-259,000	-249,000	-526,000	-448,000	-515,000	-572,000	-571,000	-593,000	-1,200,000	-723,000	-766,000	-1,178,000	-2,260,000	-2,345,000	-1,685,000	-1,363,000	-2,145,000	-1,860,000	-1,144,000	-959,000	-1,354,000	-696,000	-689,000	-656,000	-677,000
non-cash interest expense	17,000	17,000	23,000	27,000	28,000	29,000	28,000	34,000	36,000	43,000	46,000	169,000	197,000	309,000	428,000	479,000	506,000	558,000	761,000	760,000	771,000	791,000	1,074,000	1,053,000	1,039,000	993,000
net accretion and amortization of investments in marketable securities	-354,000		-541,000	-668,000	-718,000	-923,000	-983,000	-676,000	-553,000	-619,000	-658,000	-534,000	-385,000	-224,000	-81,000	83,000	168,000	246,000	300,000	294,000	159,000	139,000	31,000	42,000	-2,000
net change in operating items:
accounts receivable	1,160,000	-129,000	120,000	157,000	1,227,000	-801,000	159,000	372,000	-363,000	395,000	443,000	50,000	-1,312,000	483,000	135,000	-657,000	-414,000	768,000	-369,000	-33,000	47,000	-237,000	33,000	-36,000	132,000	1,184,000	-349,000	-1,116,000	508,000	-1,813,000	1,387,000	-286,000	-317,000	-325,000	-6,495,000	14,296,000	-7,605,000	674,000	177,000	-784,000	668,000	-3,419,000	5,785,000	1,148,000	-2,886,000	-35,000	-3,083,000	2,640,000	-1,409,000	3,263,770	-2,135,855	184,747	-423,733	-88,746	-635,533	2,040,043	-1,504,508	-171,549	3,441,352	-830,133	-1,634
license receivable from genevant	-178,741,000
prepaid expenses and other assets	-195,000	1,298,000	1,040,000	-1,053,000	413,000	1,153,000	1,185,000	116,000	-156,000	1,097,000	-1,463,000	-109,000	-468,000	2,403,000	1,153,000	381,000	-1,507,000	-958,000	374,000	416,000	-857,000	-1,102,000	317,000	472,000	-439,000	526,000			2,110,000	-757,000	-113,000	-465,000	687,000	-916,000	92,000	255,000	-264,000	-699,000	1,157,000	-300,000	-273,000	-310,000	988,000	-740,000	221,000	-390,000	-626,000	-239,000	482,000	-738,318	-12,378	412,940	-438,256	177,736	-252,565	263,376	-91,769	134,325	-92,751	-195,340	44,436
accounts payable and accrued liabilities	-985,000	806,000	145,000	-7,601,000	4,545,000	20,000	-3,564,000	2,861,000	-2,024,000	465,000	1,001,000	-848,000	-6,376,000	3,760,000	-204,000	3,762,000	-2,102,000	1,326,000	1,167,000	2,214,000	-2,796,000	1,813,000	1,251,000	2,204,000	-3,602,000	-2,948,000	-350,000	3,634,000	-2,746,000	-2,360,000	173,000	5,108,000	-4,187,000	2,541,000	-4,010,000	6,114,000	-3,909,000	913,000	-929,000	1,158,000	-1,116,000	-4,897,000	9,759,000	-9,359,000	2,008,000	3,896,000	3,300,000	-1,994,000	1,051,000	905,568	-1,367,607	-227,739	819,775	-272,779	185,005	798,724	-907,214	-1,267,754	-861,882	1,409,945	-1,459,681
change in deferred license revenue		0	0	-9,622,000	-812,000	-477,000	-123,000	-513,000	-244,000		-3,221,000
other liabilities	-105,000	-177,000	-155,000	-121,000	-104,000	-124,000	-156,000	-78,000	-72,000	-155,000	-142,000	-73,000	-74,000	-124,000	-132,000	-74,000	-75,000		-125,000	-2,000	-116,000		-134,000	-20,000	-131,000	-219,000			-87,000
net cash from operating activities	-8,110,000	-4,680,000	-5,817,000	-15,749,000	-13,391,000	-10,315,000	-20,736,000	-14,504,000	-19,295,000	-17,292,000	-21,784,000	-19,559,000	-27,301,000	-16,990,000	-18,692,000	-20,293,000	20,619,000	-19,606,000	-16,036,000	-14,009,000	-17,881,000	-15,013,000	-12,174,000	-8,801,000	-15,453,000	-47,536,000	-5,865,000	-1,025,000	-16,580,000	-54,662,000	4,418,000	2,345,000	-19,967,000	-32,960,000	-10,602,000	12,457,000	-17,535,000	-43,173,000	2,092,000	-5,258,000	-11,546,000			1,172,000	-17,843,000	-5,701,000	1,290,000	-17,165,000	9,155,000	-2,982,945	-830,682	-20,453	-2,904,479	34,393,159	490,746	2,466,671	-4,252,020
capital expenditures	0	0	0	0		-86,000	0	-1,000	-95,000	0	-32,000	-859,000	-117,000	-134,000	-91,000	-212,000	-75,000	-58,000	-20,000	-632,000	-99,000	-152,000	-11,000	0		-334,000	-15,000	-209,000	-31,000	-901,000	188,000	-177,000	-248,000	-6,726,000	2,583,000	302,000	-3,423,000	-3,828,000	786,000	-678,000	-276,000			-242,000	-141,000	-904,000	94,000	89,000	-335,000	-601,935	94,077	-10,703	-206,539	0	0	-11,089	-839
free cash flows	-8,110,000	-4,680,000	-5,817,000	-15,749,000		-10,401,000	-20,736,000	-14,505,000	-19,390,000	-17,292,000	-21,816,000	-20,418,000	-27,418,000	-17,124,000	-18,783,000	-20,505,000	20,544,000	-19,664,000	-16,056,000	-14,641,000	-17,980,000	-15,165,000	-12,185,000	-8,801,000		-47,870,000	-5,880,000	-1,234,000	-16,611,000	-55,563,000	4,606,000	2,168,000	-20,215,000	-39,686,000	-8,019,000	12,759,000	-20,958,000	-47,001,000	2,878,000	-5,936,000	-11,822,000			930,000	-17,984,000	-6,605,000	1,384,000	-17,076,000	8,820,000	-3,584,880	-736,605	-31,156	-3,111,018	34,393,159	490,746	2,455,582	-4,252,859
investing activities
purchase of investments in marketable securities	-13,800,000	-25,547,000	-51,300,000	-28,498,000	-34,716,000	-43,191,000	-40,336,000	-32,585,000	-25,397,000	-24,019,000	-7,085,000	-29,200,000	-20,205,000
disposition of investments in marketable securities	16,000,000	23,831,000	41,281,000	44,100,000	46,065,000	56,688,000	28,350,000	42,415,000	37,186,000	46,244,000	17,526,000	31,500,000	37,000,000
net cash from investing activities	2,199,000	-1,361,000	-10,019,000	15,611,000	11,349,000	13,411,000	-11,986,000	9,829,000	11,694,000	22,225,000	10,429,000	1,441,000	16,678,000	12,682,000	-13,738,000	-13,830,000	-60,056,000	-8,121,000				-49,976,000	14,097,000	23,371,000	-2,401,000																					-42,515,000	42,795,000	-42,903,000	-335,000	-601,935			-206,539	-14,822	14,416	-11,089	-839
financing activities
issuance of common shares pursuant to exercise of stock options	11,531,000	1,640,000	794,000	453,000	2,653,000	1,422,000	1,590,000	2,011,000	2,454,000	1,000	0	0	259,000
issuance of common shares pursuant to espp	88,000	0	50,000	0	131,000										159,000	0	236,000		214,000	0	247,000
net cash from financing activities	11,619,000	1,640,000	844,000	453,000	2,784,000	1,421,000	1,775,000	24,370,000	24,430,000	3,807,000	1,681,000	4,742,000	20,417,000	11,084,000	9,132,000	113,000	11,485,000	59,121,000	46,952,000	4,289,000	26,874,000	20,210,000	49,096,000	4,959,000	12,481,000	18,908,000	16,070,000	-57,000	2,536,000	55,211,000	-300,000	-53,632,000	54,367,000	49,261,000	57,000	-350,000	354,000	12,562,000	-370,000	331,000	115,000	143,754,000	-844,000	-141,860,000	142,820,000	59,992,000	450,000	-59,055,000	59,289,000	32,638,098	7,446	-70,958	141,875	4,540,795	3,340	-3,842,415	3,842,715
effect of foreign exchange rate changes on cash and cash equivalents	-10,000	1,000	-12,000	21,000	4,000	-33,000	5,000	-8,000	-13,000	14,000	8,000	-1,000	4,000	-4,000						0	-44,000	112,000	0	-46,000	-10,000	92,000	-81,000	19,000	38,000		492,000	204,000	-565,000		502,000	401,000	424,000		-773,000	-3,057,000	3,006,000			3,401,000	-2,434,000	-1,216,000
increase in cash and cash equivalents	5,698,000	-4,400,000	-15,004,000	336,000	746,000	4,484,000	-30,942,000	19,687,000	16,816,000				9,798,000	6,772,000			-27,952,000	31,399,000	46,929,000	-48,467,000	27,170,000	-44,667,000	51,019,000	19,483,000	-5,383,000							39,563,000	-41,831,000	39,866,000	-3,348,000	-12,077,000	6,438,000	-127,026,000	85,462,000	-79,795,000	-22,007,000			-185,160,000	160,089,000	10,560,000	42,000,000	-114,730,000	65,640,000				-2,975,595			-1,368,286	-439,060
cash and cash equivalents, beginning of period	18,008,000	0	0	0	36,330,000	0	0	0	26,285,000	0	0	0	30,776,000	0	0	0	109,282,000	0	0	0	52,251,000	0	0	0	31,799,000	-41,930,000						-41,831,000	54,292,000	-799,000	-5,639,000	6,438,000	23,413,000	123,809,000	-101,802,000	-22,007,000	166,779,000	-135,018,000	-25,071,000	160,089,000	72,187,000	-16,550,000	-49,090,000	65,640,000	68,717,000		-3,073,919	-2,975,595	46,785,518	2,246,406	-1,807,346	-439,060	9,184,134	3,117,345	0	-3,117,345	12,346,010
cash and cash equivalents, end of period	23,706,000	-4,400,000	-15,004,000	336,000	37,076,000	4,484,000	-30,942,000	19,687,000	43,101,000	8,754,000	-9,666,000	-13,377,000	40,574,000	6,772,000	-23,316,000	-34,010,000	81,330,000	31,399,000	46,929,000	-48,467,000	79,421,000	-44,667,000	51,019,000	19,483,000	26,416,000	-58,283,000						-2,268,000	12,461,000	39,067,000	-8,987,000	-5,639,000	29,851,000	-3,217,000	-16,340,000	-101,802,000	144,772,000	-14,310,000	-26,116,000	-25,071,000	232,276,000	-5,990,000	-7,090,000	-49,090,000	134,357,000		-3,816,932	-3,073,919	43,809,923	41,152,626	-1,304,836	-1,807,346	8,745,074	451,840	-979,326	482,955	9,228,665
net loss		-3,756,000	-7,742,000			-12,532,000	-19,717,000	-19,796,000	-17,875,000	-19,312,000	-20,104,000	-17,094,000	-16,339,000	-21,932,000	-17,567,000	-14,192,000	-15,765,000	-21,321,000	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000
depreciation and amortization
gain on sale of property and equipment										0					0													7,000	-9,000	0
net accretion of investments in marketable securities
proceeds from sale of property and equipment		355,000	0							0					0													-7,000	9,000	0	23,000																							2
acquisition of property and equipment						-86,000	0	-1,000	-95,000	0	-32,000	-859,000	-117,000	-134,000	-91,000	-212,000	-75,000	-58,000	-20,000	-632,000	-99,000	-152,000	-11,000			-334,000	-15,000	-209,000	-31,000	-901,000	188,000	-177,000	-248,000	-6,726,000	2,583,000	302,000	-3,423,000	-3,828,000	786,000	-678,000	-276,000			-242,000	-141,000	-904,000	94,000	89,000	-335,000	-601,935	94,077	-10,703	-206,539			-11,089	-839			54,068	-55,258
issuance of common shares pursuant to the open market sale agreement						-1,000	0	22,359,000	21,765,000	3,852,000	1,396,000	4,742,000	19,862,000		8,973,000	0	268,000		44,736,000	4,274,000	26,419,000		48,760,000	5,045,000	12,315,000			229,000	2,248,000
loss on impairment of lab equipment						0
issuance of common shares pursuant to exercise of espp								0	211,000	-46,000	285,000	0	296,000
deferred license revenue													-4,104,000	-3,008,000	-2,352,000	-11,025,000	38,840,000
issuance of common shares pursuant to share purchase agreement														0	0	0	10,973,000
decrease in cash and cash equivalents										8,754,000	-9,666,000																																								-743,013										-3,117,345
issuance of common shares pursuant to the atm
supplemental cash flow information
preferred shares dividends accrued																		-574,000	-5,087,000	-3,266,000	-3,212,000	-3,123,000	-3,027,000	-2,995,000	-2,978,000	-8,357,000	-5,554,000	47,000	2,715,000	7,524,000	26,000
purchase of investments															-32,647,000	-22,638,000	-61,981,000		-11,000	-52,115,000	-2,030,000		-2,992,000	-1,543,000	-24,369,000
disposition of investments															19,000,000	9,000,000	2,000,000		16,000,000	14,000,000	20,350,000		19,600,000	24,980,000	21,968,000
issuance of common shares pursuant to exercise of options															0	113,000	8,000	-115,000	2,002,000	15,000	208,000	33,000	336,000	-86,000	166,000			-286,000	288,000	947,000	-300,000	632,000	103,000	39,000	57,000	3,000	1,000	116,000	75,000	-114,000	115,000	1,535,000	-823,000	319,000	620,000	2,348,000	120,000	-1,776,000	1,924,000	366,526	14,877	-76,183	84,100	67,405	3,340	-900	1,200	1,508			1,436
unrealized foreign exchange losses																				0	44,000		0	46,000	10,000	-92,000	81,000	-19,000	-38,000		-492,000	-204,000	565,000		-504,000	-399,000	-425,000		775,000	3,057,000	-3,006,000			9,696,000	-7,057,000	-973,000	-4,636,000	1,450,000	-59,000
unrealized foreign exchange gains
net equity investment loss																						1,000
lease liabilities
investment in genevant																						0
issuance of common shares pursuant to exercise of espp options
issuance of common shares pursuant to the open market sales agreement
restructuring accrual
net cash (used) provided by investing activities
net cash provided (used) by investing activities																					18,221,000
deferred income tax benefit																										0				0
loss on sale of property and equipment
impairment of intangible assets																										0				0												1,017,000
impairment of goodwill																										0
proceeds from sale of future royalties
items not involving cash:
net equity investment gain
net loss for the period																													-23,251,000				-17,429,000	-72,813,000	6,655,000	372,000	-18,627,000	-364,569,000	110,405,000	-114,126,000	-15,874,000
site consolidation non-cash portion
net change in non-cash operating items:
accrued revenue																																												2,430,000	-1,126,000	-399,000	-181,000	428,000	-208,000	-49,781	1,795,234	1,411,718	-1,148,956	-2,187,291	65,921	-186,989	131,879	1,002,960	-194,168	-791,394	614,710
investment tax credits receivable																													98,000				-2,000			309,000	-15,000													-40,788				113,572	94,063
deferred revenue																														-2,417,000	421,000	276,000	-1,022,000	9,466,000	-6,086,000	-8,045,000	7,392,000	-370,000	-483,000	-56,000	-157,000	-16,101,000	2,677,000	1,625,000	-1,291,000	13,977,000	-1,261,000	-11,834,000	12,289,000	-644,490	1,267,784	-1,630,139	853,707	-421,054	82,456	-469,561	156,140	944,529	-1,142,427	194,082	364,501
site consolidation accrual																												-501,000	-139,000	1,651,000	-381,000	-968,000	1,029,000
acquisition of investments																																														-41,691,000	42,701,000
proceeds from the sale of future royalties
promissory note repayment																																	-12,001,000
proceeds from sale of preferred shares, net of issuance costs
issuance of common shares pursuant to open market sales agreement
initial investment in genevant
interest paid
gain on investment
equity investment loss																											178,000	-1,317,000	4,651,000	2,489,000
acquisition of short and long-term investments
disposition of short and long-term investments
net cash from (used) in investing activities																											6,183,000	-51,061,000	61,033,000		9,398,000	90,646,000	-75,666,000		6,695,000	-24,585,000	23,195,000		84,513,000	-71,811,000	-13,582,000			-47,873,000	37,546,000
proceeds from sale of series a preferred shares, net of issuance costs																																	66,265,000
non-cash transactions:
net income for the period																																													-11,989,000
depreciation of property and equipment																												-4,000	509,000	1,684,000	-81,000	-24,000	602,000	1,434,000	113,000	146,000	334,000	801,000	39,000	35,000	217,000	436,000	6,000	27,000	120,000	396,000	-16,000	15,000	134,000	459,985	-4,070	-13,705	170,627	650,340	-11,248	-14,888	240,837	721,714	15,512	-363	238,649
gain on equity investment
prepaid expenses and other current assets
other non-current liabilities
acquisition of short-term investments
disposition of short-term investments																												-50,845,000	61,055,000																37,363,000
increase in cash, cash equivalents, and restricted investment																												-52,124,000	47,027,000
cash, cash equivalents, and restricted investment, beginning of period																												47,027,000	36,942,000
cash, cash equivalents, and restricted investment, end of period																												-5,097,000	83,969,000
other assets																													167,000
stock-based compensation
change in fair value of warrant liability																																					22,000	-520,000	158,000	-7,000	-161,000			-3,247,000	1,223,000	5,243,000	10,953,000	-19,429,000	13,616,000	1,022,255	2,478,873	346,683	-317,497	2,074,436	2,379,756	-1,147,388	512,366	-295,334	-125,293
deferred rent and inducements
disposition (acquisition) of investments
issuance of common shares pursuant to exercise of warrants																																					353,000							-6,000	25,000	1,167,000	330,000	-802,000	888,000	233,255	-7,431	5,225	57,775
effect of foreign currency rate changes on cash and cash equivalents
investment tax credits received																																																		50				113,572	94,063
net (loss) for the period
stock-based compensation - research, development, collaborations and contract expenses																															-566,000	1,084,000	783,000	6,768,000	-587,000	433,000	2,622,000	8,396,000	240,000	-428,000	2,947,000	5,198,000	1,294,000	-780,000	2,157,000	2,017,000	-466,000	-56,000	848,000
stock-based compensation - general and administrative expenses																															-267,000	622,000	172,000	4,370,000	-537,000	167,000	1,881,000	26,309,000	-17,897,000	14,627,000	4,965,000	9,392,000	786,000	3,269,000	777,000	821,000	-170,000	-51,000	340,000
deferred lease incentives
disposition (acquisition) of short and long-term investments																															9,187,000	90,821,000	-75,418,000		4,112,000	-24,887,000	26,618,000		83,727,000	-71,133,000	-13,306,000
investment tax credit received																																			0
acquired property and equipment in trade payables																																				-1,355,000	1,427,000
deferred income taxes
acquisition of restricted investment
cash acquired through acquisition
proceeds from loan payable
proceeds from issuance of common shares, net of issuance costs																																												-142,173,000	142,175,000				56,477,000
acquisition of property and equipment not yet paid
acquisition of arbutus inc. net of cash acquired
deferred expenses																																														111,000	-1,000	2,000	55,000	178,585	-9,300	-1	61,318	217,544	98,255	-72,472	115,563	-305,334	75,004	5,376	-5,901
fair value of warrants exercised on a cashless basis																																																		706,229	585,620	2,775	109,725
acquisition of arbutus inc. excluding cash acquired
cash acquired through acquisition of oncore																																													324,000
acquisition of oncore exclusing cash acquired																																													381,618,000
warrant issuance costs																																																									47,000
fair value of warrants issued in conjunction with public offering
loss for the period																																															-2,523,000	11,903,000	-17,984,000		-2,977,479	-482,704	-2,622,415		-1,512,086	1,236,523	-3,159,878	-8,467,631	2,062,773	-434,359	-3,097,709
effect of foreign exchange rate changes on cash & cash equivalents																																																4,393,000	-2,469,000
income for the year
fair value of warrants issued in conjunction with debt facility
inventory																																																										-60,316	422,094	-361,778	150,731
proceeds from issuance of common shares and warrants, net of issuance costs																																																									3,841,515
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
foreign exchange losses arising on foreign currency cash balances																																																			13,854	-3,790	6,452	12,911	5,993	-18,547	28,916	43,351	-89,702	21,610	4,646
net cash from used in investing activities
foreign exchange gains arising on foreign currency cash balances																																																					-6,452	-12,911	-5,993	18,547	-28,916				-4,646
proceeds from (acquisition of) short-term investments, ne
financing activities - sum																																																											-4,536,494	4,544,211	1,436
investing activities - sum																																																												54,068	-55,258

Arbutus Biopharma Corporation(NASDAQ:ABUS)

Arbutus Biopharma Corporation
(NASDAQ:ABUS)